Mercado mundial de retinopatía diabética: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado mundial de retinopatía diabética

En los últimos años, se prevé que el mercado de la retinopatía diabética crezca rápidamente durante el período de pronóstico. La retinopatía diabética (RD) es la causa más común de pérdida visual en todo el mundo. La duración de la hiperglucemia, la diabetes y la hipertensión son los factores de riesgo clínicamente más importantes para la progresión de la pérdida de la visión. Se ha demostrado que controlar el azúcar en sangre y la presión arterial ayuda a prevenir la pérdida de visión debido a la retinopatía diabética. Según la Federación Internacional de Diabetes (FID), la prevalencia mundial de diabetes mellitus (DM) fue de alrededor del 27% entre 2015 y 2019. Las tasas más bajas se encontraron en Europa (20,6%) y el sudeste asiático (12,5%), mientras que las tasas más significativas se encontraron en África (33,8%), Oriente Medio y África del Norte (33,8%) y la región del Pacífico Occidental (36,2%).

• Data Bridge Market Research analiza que el mercado de la retinopatía diabética se valoró en USD 6.60 mil millones en 2021 y se espera que alcance los USD 12.68 mil millones para 2029, registrando una CAGR del 8,50% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición del mercado mundial de retinopatía diabética

La diabetes mellitus daña los vasos sanguíneos de la retina, lo que produce retinopatía diabética (RD). Existen dos tipos de retinopatía diabética: la no proliferativa y la proliferativa o progresiva. Es causada por cambios en los niveles de glucosa en sangre, que provocan un crecimiento anormal de las estructuras sensibles a la luz en el ojo. Las manchas oscuras o hilos flotantes en el campo visual, la visión borrosa o fluctuante, la disminución de la visión de los colores o la pérdida de la visión son síntomas de la retinopatía diabética.

Alcance del informe y segmentación del mercado

Dinámica del mercado de la retinopatía diabética

Conductores

• Aumento de la prevalencia de la diabetes

La creciente prevalencia de la diabetes es un factor principal del crecimiento del mercado de la retinopatía diabética. Junto con esto, el aumento de los casos de ceguera debido a la diabetes influirá aún más en la dinámica del mercado durante el período de pronóstico.   

• Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de la retinopatía diabética es el creciente gasto en atención médica, que ayuda a mejorar su infraestructura.

Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la información ampliarán el mercado de la retinopatía diabética. Además, los altos ingresos disponibles y el escenario favorable de reembolso darán lugar a la expansión del mercado de la retinopatía diabética. Junto con esto, la creciente población geriátrica y el estilo de vida en constante cambio mejorarán la tasa de crecimiento del mercado.

Oportunidades

• Aumento del número de actividades de investigación y desarrollo       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the diabetic retinopathy market growth. Along with this, rising approvals and launches of new diabetic retinopathy drugs will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the diabetic retinopathy market growth during the forecast period.

Restraints/Challenges Global Diabetic Retinopathy Market

On the other hand, the high cost associated with the treatment of diabetic retinopathy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the diabetic retinopathy market. Additionally, a decline in clinical visits due to COVID-19 outbreak and post-surgical complications will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This diabetic retinopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic retinopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Diabetic retinopathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Diabetic Retinopathy Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems worldwide have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of diabetic retinopathy in recent months.

Recent Development

• In August 2020, Eyenuk had announced the U.S. Food and Drug Administration (FDA) approval for EyeArt Autonomous AI System for diabetic retinopathy screening. EyeArt is designed to help healthcare providers detect more than moderate diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in the eyes of adults with diabetes who have never been diagnosed with more than mild diabetic retinopathy.

Global Diabetic Retinopathy Market Scope

The diabetic retinopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Type segment for the diabetic retinopathy market is categorized into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.

Treatment

• Medication
• Device
• Surgery
• Others

Based on treatment, the diabetic retinopathy market is segmented into medication, device, surgery and others. The medication section is further categorized into anti-vascular endothelial growth factor drug, intravitreal steroid, lipid lowering drugs and others. The device section has been sub-segmented into focal laser, vitrectomy devices, scatter laser and others.

Diagnosis

• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Based on diagnosis, the diabetic retinopathy market is segmented into fluorescein angiography, optical coherence tomography and others.

Route of Administration

• Oral
• Intravitreal Injections
• Intravitreal Implants
• Others

The route of administration segment for global diabetic retinopathy market is segmented into oral, intravitreal injections, intravitreal implants and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the diabetic retinopathy market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the diabetic retinopathy market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Diabetic Retinopathy Market Regional Analysis/Insights

The diabetic retinopathy market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Diabetic retinopathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the diabetic retinopathy market because of the growing prevalence of diabetic retinopathy and the presence of refined healthcare expenditure in this region. Additionally, growing focus of major key players on novel technology will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to the population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Diabetic Retinopathy Market Share Analysis

The Diabetic retinopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic retinopathy market.

Some of the major players operating in the diabetic retinopathy market are:

• LEO Pharma A/S (Denmark)
• Amneal Pharmaceuticals LLC. (US)
• Glenmark Pharmaceuticals Limited (India)
• Dr. 'Reddy's Laboratories Ltd. (India)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (Estados Unidos)
• Bausch Health Companies Inc. (Canadá)
• Eli Lilly and Company (Estados Unidos)
• AbbVie Inc. (Estados Unidos)
• Abbott (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Novartis AG (Suiza)
• Industrias farmacéuticas Sun Ltd. (India)
• Aurobindo Pharma (India)
• Lupino (India)
• Allergan (Irlanda)
• Merck & Co., Inc. (Estados Unidos)
• Corporación IRIDEX (Estados Unidos)
• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)

SKU-53232